Are branded and generic extended-release ropinirole formulations equally efficacious? A rater-blinded, switch-over, multicenter study

Edit Bosnyák, Mihály Herceg, Endre Pál, Zsuzsanna Aschermann, J. Janszky, Ildikó Késmárki, S. Komoly, Kázmér Karádi, T. Dóczi, Ferenc Nagy, N. Kovács

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The aim of this study was to compare the efficacy of the branded and a generic extended-release ropinirole formulation in the treatment of advanced Parkinson's disease (PD). Of 22 enrolled patients 21 completed the study. A rater blinded to treatment evaluated Unified Parkinson's Disease Rating Scale, Fahn-Tolosa-Marin Tremor Rating Scale, Nonmotor Symptoms Assessment Scale, and a structured questionnaire on ropinirole side effects. Besides, the patients self-administered EQ-5D, Parkinson's Disease Sleep Scale (PDSS-2), and Beck Depression Inventories. Branded and generic ropinirole treatment achieved similar scores on all tests measuring severity of motor symptoms (primary endpoint, UPDRS-III: 27.0 versus 28.0 points, P = 0.505). Based on patient diaries, the lengths of "good time periods" were comparable (10.5 and 10.0 hours for branded and generic ropinirole, resp., P = 0.670). However, generic ropinirole therapy achieved almost 3.0 hours shorter on time without dyskinesia (6.5 versus. 9.5 hours, P <0.05) and 2.5 hours longer on time with slight dyskinesia (3.5 versus. 1.0 hours, P <0.05) than the branded ropinirole did. Except for gastrointestinal problems, nonmotor symptoms were similarly controlled. Patients did not prefer either formulation. Although this study has to be interpreted with limitations, it demonstrated that both generic and branded ropinirole administration can achieve similar control on most symptoms of PD.

Original languageEnglish
Article number158353
JournalParkinson's Disease
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Multicenter Studies
Parkinson Disease
Dyskinesias
Symptom Assessment
Tremor
Therapeutics
ropinirole
Sleep
Depression
Equipment and Supplies

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Are branded and generic extended-release ropinirole formulations equally efficacious? A rater-blinded, switch-over, multicenter study. / Bosnyák, Edit; Herceg, Mihály; Pál, Endre; Aschermann, Zsuzsanna; Janszky, J.; Késmárki, Ildikó; Komoly, S.; Karádi, Kázmér; Dóczi, T.; Nagy, Ferenc; Kovács, N.

In: Parkinson's Disease, Vol. 2014, 158353, 2014.

Research output: Contribution to journalArticle

Bosnyák, Edit ; Herceg, Mihály ; Pál, Endre ; Aschermann, Zsuzsanna ; Janszky, J. ; Késmárki, Ildikó ; Komoly, S. ; Karádi, Kázmér ; Dóczi, T. ; Nagy, Ferenc ; Kovács, N. / Are branded and generic extended-release ropinirole formulations equally efficacious? A rater-blinded, switch-over, multicenter study. In: Parkinson's Disease. 2014 ; Vol. 2014.
@article{6d7158f7fb684065a8259be2b3cfd8b5,
title = "Are branded and generic extended-release ropinirole formulations equally efficacious? A rater-blinded, switch-over, multicenter study",
abstract = "The aim of this study was to compare the efficacy of the branded and a generic extended-release ropinirole formulation in the treatment of advanced Parkinson's disease (PD). Of 22 enrolled patients 21 completed the study. A rater blinded to treatment evaluated Unified Parkinson's Disease Rating Scale, Fahn-Tolosa-Marin Tremor Rating Scale, Nonmotor Symptoms Assessment Scale, and a structured questionnaire on ropinirole side effects. Besides, the patients self-administered EQ-5D, Parkinson's Disease Sleep Scale (PDSS-2), and Beck Depression Inventories. Branded and generic ropinirole treatment achieved similar scores on all tests measuring severity of motor symptoms (primary endpoint, UPDRS-III: 27.0 versus 28.0 points, P = 0.505). Based on patient diaries, the lengths of {"}good time periods{"} were comparable (10.5 and 10.0 hours for branded and generic ropinirole, resp., P = 0.670). However, generic ropinirole therapy achieved almost 3.0 hours shorter on time without dyskinesia (6.5 versus. 9.5 hours, P <0.05) and 2.5 hours longer on time with slight dyskinesia (3.5 versus. 1.0 hours, P <0.05) than the branded ropinirole did. Except for gastrointestinal problems, nonmotor symptoms were similarly controlled. Patients did not prefer either formulation. Although this study has to be interpreted with limitations, it demonstrated that both generic and branded ropinirole administration can achieve similar control on most symptoms of PD.",
author = "Edit Bosny{\'a}k and Mih{\'a}ly Herceg and Endre P{\'a}l and Zsuzsanna Aschermann and J. Janszky and Ildik{\'o} K{\'e}sm{\'a}rki and S. Komoly and K{\'a}zm{\'e}r Kar{\'a}di and T. D{\'o}czi and Ferenc Nagy and N. Kov{\'a}cs",
year = "2014",
doi = "10.1155/2014/158353",
language = "English",
volume = "2014",
journal = "Parkinson's Disease",
issn = "2090-8083",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Are branded and generic extended-release ropinirole formulations equally efficacious? A rater-blinded, switch-over, multicenter study

AU - Bosnyák, Edit

AU - Herceg, Mihály

AU - Pál, Endre

AU - Aschermann, Zsuzsanna

AU - Janszky, J.

AU - Késmárki, Ildikó

AU - Komoly, S.

AU - Karádi, Kázmér

AU - Dóczi, T.

AU - Nagy, Ferenc

AU - Kovács, N.

PY - 2014

Y1 - 2014

N2 - The aim of this study was to compare the efficacy of the branded and a generic extended-release ropinirole formulation in the treatment of advanced Parkinson's disease (PD). Of 22 enrolled patients 21 completed the study. A rater blinded to treatment evaluated Unified Parkinson's Disease Rating Scale, Fahn-Tolosa-Marin Tremor Rating Scale, Nonmotor Symptoms Assessment Scale, and a structured questionnaire on ropinirole side effects. Besides, the patients self-administered EQ-5D, Parkinson's Disease Sleep Scale (PDSS-2), and Beck Depression Inventories. Branded and generic ropinirole treatment achieved similar scores on all tests measuring severity of motor symptoms (primary endpoint, UPDRS-III: 27.0 versus 28.0 points, P = 0.505). Based on patient diaries, the lengths of "good time periods" were comparable (10.5 and 10.0 hours for branded and generic ropinirole, resp., P = 0.670). However, generic ropinirole therapy achieved almost 3.0 hours shorter on time without dyskinesia (6.5 versus. 9.5 hours, P <0.05) and 2.5 hours longer on time with slight dyskinesia (3.5 versus. 1.0 hours, P <0.05) than the branded ropinirole did. Except for gastrointestinal problems, nonmotor symptoms were similarly controlled. Patients did not prefer either formulation. Although this study has to be interpreted with limitations, it demonstrated that both generic and branded ropinirole administration can achieve similar control on most symptoms of PD.

AB - The aim of this study was to compare the efficacy of the branded and a generic extended-release ropinirole formulation in the treatment of advanced Parkinson's disease (PD). Of 22 enrolled patients 21 completed the study. A rater blinded to treatment evaluated Unified Parkinson's Disease Rating Scale, Fahn-Tolosa-Marin Tremor Rating Scale, Nonmotor Symptoms Assessment Scale, and a structured questionnaire on ropinirole side effects. Besides, the patients self-administered EQ-5D, Parkinson's Disease Sleep Scale (PDSS-2), and Beck Depression Inventories. Branded and generic ropinirole treatment achieved similar scores on all tests measuring severity of motor symptoms (primary endpoint, UPDRS-III: 27.0 versus 28.0 points, P = 0.505). Based on patient diaries, the lengths of "good time periods" were comparable (10.5 and 10.0 hours for branded and generic ropinirole, resp., P = 0.670). However, generic ropinirole therapy achieved almost 3.0 hours shorter on time without dyskinesia (6.5 versus. 9.5 hours, P <0.05) and 2.5 hours longer on time with slight dyskinesia (3.5 versus. 1.0 hours, P <0.05) than the branded ropinirole did. Except for gastrointestinal problems, nonmotor symptoms were similarly controlled. Patients did not prefer either formulation. Although this study has to be interpreted with limitations, it demonstrated that both generic and branded ropinirole administration can achieve similar control on most symptoms of PD.

UR - http://www.scopus.com/inward/record.url?scp=84929190290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929190290&partnerID=8YFLogxK

U2 - 10.1155/2014/158353

DO - 10.1155/2014/158353

M3 - Article

AN - SCOPUS:84929190290

VL - 2014

JO - Parkinson's Disease

JF - Parkinson's Disease

SN - 2090-8083

M1 - 158353

ER -